Core Viewpoint - Changfeng Pharmaceutical has successfully completed the first patient enrollment for its self-developed bronchial valve lung volume reduction device, marking the official start of the clinical validation phase aimed at providing a minimally invasive treatment option for patients with emphysema and chronic obstructive pulmonary disease (COPD) [1] Company Summary - Changfeng Pharmaceutical's stock rose nearly 3%, currently trading at 29.2 HKD with a transaction volume of 5.3645 million HKD [1] - The successful completion of the first patient enrollment signifies the entry of this innovative minimally invasive device into the clinical validation stage [1] Industry Summary - The device targets unmet clinical needs in the management of emphysema, which is characterized by dynamic hyperinflation and limited activity [1] - The clinical study will focus on safety monitoring during the perioperative period and multi-dimensional assessments of imaging and lung function, with key indicators including device-related safety, technical success rate, and changes in clinical outcomes such as FEV1, RV, 6MWD, and SGRQ [1] - The research data will form an auditable evidence chain for future registration strategies and commercialization decisions [1]

Core Viewpoint - Changfeng Pharmaceutical (02652) has initiated the clinical validation phase for its self-developed bronchial valve lung volume reduction device, marking a significant step towards providing a minimally invasive treatment option for patients with emphysema and chronic obstructive pulmonary disease (COPD) [1] Group 1: Company Developments - The stock price of Changfeng Pharmaceutical increased by 2.74%, reaching HKD 29.2, with a trading volume of HKD 5.3645 million [1] - The first patient enrollment (FPI) for the clinical trial has been successfully completed, officially commencing the clinical validation phase [1] - The device aims to address unmet clinical needs in long-term management and quality of life improvement for emphysema patients, who often experience dynamic hyperinflation and activity limitations [1] Group 2: Clinical Research Details - The clinical study will focus on continuous enrollment, perioperative safety monitoring, and multi-dimensional assessments of imaging and lung function [1] - Key indicators will include safety related to the device and procedure, technical success rates, and changes in critical clinical outcomes such as FEV1, RV, 6MWD, and SGRQ [1] - The research data will create an auditable evidence chain for future registration strategies and commercialization decisions [1]

Core Viewpoint - The successful implementation of the first transradial approach liver hemangioma embolization in Dongying marks a significant advancement in minimally invasive interventional treatment at Shengli Oilfield Central Hospital, enhancing patient comfort and recovery speed [1][3]. Group 1: Surgical Innovation - The patient, a 35-year-old woman, underwent the procedure due to multiple liver hemangiomas, with the largest measuring 5.3 cm and showing significant growth [1]. - The innovative transradial approach allows for precise catheter delivery to the target blood vessels of the liver hemangioma, injecting embolic agents to block blood supply, leaving only a small puncture mark [1][3]. - This new technique avoids the long recovery time associated with traditional femoral artery puncture, significantly reducing the risk of venous thrombosis and pulmonary embolism, while also shortening hospital stays [1][3]. Group 2: Commitment to Patient-Centric Care - The interventional department has recently achieved breakthroughs in various advanced techniques, expanding the application of minimally invasive technologies [3]. - The department head emphasizes that patient-centered technological innovation is crucial for implementing the "accelerated recovery" concept [3]. - The success of this procedure not only provides a less invasive and quicker recovery option for liver hemangioma patients but also injects new momentum into the development of interventional medicine in the Dongying region [3].